{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:33Z","timestamp":1793659773532,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.annonc.2022.05.521","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T15:49:38Z","timestamp":1654789778000},"page":"916-928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas"],"prefix":"10.1016","volume":"33","author":[{"given":"G.","family":"Ghilardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pajarillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hodges Dwinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Victoriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Napier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2022.05.521_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.17191","article-title":"CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before","volume":"193","author":"Ghilardi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2022.05.521_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.05.521_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2022.05.521_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.05.521_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2022.05.521_bib8","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2022.05.521_bib9","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2022.05.521_bib10","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.annonc.2022.05.521_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxicity. characterising and avoiding the problem","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.annonc.2022.05.521_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther"},{"key":"10.1016\/j.annonc.2022.05.521_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","article-title":"Fludarabine: a review of the clear benefits and potential harms","volume":"37","author":"Lukenbill","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.annonc.2022.05.521_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib15","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","article-title":"Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG\/CALGB intergroup E1496 trial","volume":"25","author":"Hochster","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003495-200161050-00009","article-title":"Bendamustine","volume":"61","author":"Balfour","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.annonc.2022.05.521_bib18","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.annonc.2022.05.521_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2022.05.521_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.13271","article-title":"Diagnosis and management of follicular lymphoma: a comprehensive review","volume":"103","author":"Dada","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.annonc.2022.05.521_bib21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bjh.15722","article-title":"Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis","volume":"184","author":"Mart\u00ednez-Calle","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2022.05.521_bib22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.05.521_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2022.05.521_bib24","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2022.05.521_bib25","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2022.05.521_bib26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2022.05.521_bib27","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.annonc.2022.05.521_bib28","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib29","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.05.521_bib30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.05.521_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422017227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422017227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:15:10Z","timestamp":1760336110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422017227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0923753422017227"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.05.521","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.05.521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}